These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38884816)

  • 1. DNA Mutational and Copy Number Variation Profiling of Primary Craniofacial Osteosarcomas by Next-Generation Sequencing.
    Zhu GG; Lu C; Petrovic I; Nafa K; Chen W; Syed A; Rana S; Klein MJ; Huang S; Wang L; Tap WD; Ghossein RA; Shah J; Hameed MR
    Head Neck Pathol; 2024 Jun; 18(1):48. PubMed ID: 38884816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GNAS mutations are not detected in parosteal and low-grade central osteosarcomas.
    Salinas-Souza C; De Andrea C; Bihl M; Kovac M; Pillay N; Forshew T; Gutteridge A; Ye H; Amary MF; Tirabosco R; Toledo SR; Baumhoer D; Flanagan AM
    Mod Pathol; 2015 Oct; 28(10):1336-42. PubMed ID: 26248895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating GNAS mutations in parosteal osteosarcoma.
    Carter JM; Inwards CY; Jin L; Evers B; Wenger DE; Oliveira AM; Fritchie KJ
    Am J Surg Pathol; 2014 Mar; 38(3):402-9. PubMed ID: 24525511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
    McHugh JB; Thomas DG; Herman JM; Ray ME; Baker LH; Adsay NV; Rabah R; Lucas DR
    Cancer; 2006 Aug; 107(3):554-62. PubMed ID: 16795069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing].
    Gao DL; Dong RF; Liu WF; Gong LH; Xu HR; Niu XH; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):370-375. PubMed ID: 36973198
    [No Abstract]   [Full Text] [Related]  

  • 6. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.
    Suehara Y; Alex D; Bowman A; Middha S; Zehir A; Chakravarty D; Wang L; Jour G; Nafa K; Hayashi T; Jungbluth AA; Frosina D; Slotkin E; Shukla N; Meyers P; Healey JH; Hameed M; Ladanyi M
    Clin Cancer Res; 2019 Nov; 25(21):6346-6356. PubMed ID: 31175097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Profiling of the Craniofacial Ossifying Fibroma by Next-Generation Sequencing.
    Bahceci DH; Grenert JP; Jordan RCK; Horvai AE
    Head Neck Pathol; 2023 Sep; 17(3):722-730. PubMed ID: 36928741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX2 (6p21.1) amplification in osteosarcoma.
    Gupta S; Ito T; Alex D; Vanderbilt CM; Chang JC; Islamdoust N; Zhang Y; Nafa K; Healey J; Ladanyi M; Hameed MR
    Hum Pathol; 2019 Dec; 94():23-28. PubMed ID: 31669178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
    Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
    Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene mutations in osteosarcomas of low-grade malignancy.
    Radig K; Schneider-Stock R; Haeckel C; Neumann W; Roessner A
    Hum Pathol; 1998 Nov; 29(11):1310-6. PubMed ID: 9824113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of osteosarcoma in children and adolescents from different age groups using a next-generation sequencing panel.
    Guimarães GM; Tesser-Gamba F; Petrilli AS; Donato-Macedo CRP; Alves MTS; de Lima FT; Garcia-Filho RJ; Oliveira R; Toledo SRC
    Cancer Genet; 2021 Nov; 258-259():85-92. PubMed ID: 34666222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
    Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
    Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.
    Joseph NM; McGill KC; Horvai AE
    Am J Surg Pathol; 2021 Jun; 45(6):812-819. PubMed ID: 33239505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification.
    Guérin M; Thariat J; Ouali M; Bouvier C; Decouvelaere AV; Cassagnau E; Aubert S; Lepreux S; Coindre JM; Valmary-Degano S; Larousserie F; Meilleroux J; Projetti F; Stock N; Galant C; Marie B; Peyrottes I; de Pinieux G; Gomez-Brouchet A
    Hum Pathol; 2016 Apr; 50():70-8. PubMed ID: 26997440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.
    Freeman SS; Allen SW; Ganti R; Wu J; Ma J; Su X; Neale G; Dome JS; Daw NC; Khoury JD
    Cancer; 2008 Sep; 113(6):1453-61. PubMed ID: 18704985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion.
    Saba KH; Cornmark L; Rissler M; Fioretos T; Åström K; Haglund F; Rosenberg AE; Brosjö O; Nord KH
    Genes Chromosomes Cancer; 2019 Oct; 58(10):731-736. PubMed ID: 31066955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.
    Chung CH; Guthrie VB; Masica DL; Tokheim C; Kang H; Richmon J; Agrawal N; Fakhry C; Quon H; Subramaniam RM; Zuo Z; Seiwert T; Chalmers ZR; Frampton GM; Ali SM; Yelensky R; Stephens PJ; Miller VA; Karchin R; Bishop JA
    Ann Oncol; 2015 Jun; 26(6):1216-1223. PubMed ID: 25712460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
    Bousquet M; Noirot C; Accadbled F; Sales de Gauzy J; Castex MP; Brousset P; Gomez-Brouchet A
    Ann Oncol; 2016 Apr; 27(4):738-44. PubMed ID: 26787232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.